Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-1: Golcadomide Plus R-CHOP in Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Golcadomide + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival at 24 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06356129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356129.